Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations
E. Zampeli1, M. Mavrommati2, H.M. Moutsopoulos3, F.N. Skopouli4
- Institute for Autoimmune Systemic and Neurological Diseases, Athens, Greece. email@example.com
- Department of Internal Medicine and Autoimmune Diseases, Euroclinic of Athens, Greece.
- Academy of Athens, Athens, Greece.
- Department of Internal Medicine and Autoimmune Diseases, Euroclinic of Athens, and Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.
2020 Vol.38, N°4 ,Suppl.126
PI 0134, PF 0141
Free to view
(click on article PDF icon to read the article)
PMID: 32083547 [PubMed]
Accepted : 08/01/2020
In Press: 18/02/2020
This study aims to characterise the clinical phenotype and autoantibody associations in an autoimmune population positive for anti-Ro52 and/or anti-Ro60 autoantibodies.
The sera of 508 individuals tested for autoantibody presence were found positive for anti-Ro52 and/or anti-Ro60. Medical records were available for 272 of them. Correlations of clinical, laboratory and other autoantibodies as well as disease phenotypes with the presence of anti-Ro52 and/or anti-Ro60 reactivity were examined.
Combined serum anti-Ro52/anti-Ro60 reactivity was the most frequent one, mostly seen in Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE) patients. In these patients this reactivity strongly associated with anti-La and/or anti-dsDNA autoantibodies. SS patients with combined anti-Ro52/anti-Ro60 and anti-La reactivity had clinical and/or laboratory risk factors for lymphoma development. Solo anti-Ro52 reactivity was primarily found in idiopathic inflammatory myopathies (IIM), primary biliary cholangitis (PBC), rheumatoid arthritis (RA) and SS patients. Solo anti-Ro52 also associated with anti-Jo1 and anti-M2 autoantibodies and with interstitial lung disease (ILD) in a context of IIM-related lung injury. ILD patients with combined anti-Ro52/anti-Ro-60 reactivity were diagnosed mostly as RA and/or SS. Solo anti-Ro60 reactivity strongly correlated with oral ulcers and co-existed with autoantibodies to Sm and nRNP/Sm.
Testing for autoantibodies against both Ro peptides may guide diagnosis, classify clinical manifestations in disease entities and define prognosis in certain autoimmune disorders. A distinct weight could be given to the isolated anti-Ro specificities in the SS classification criteria.